Announcement on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-012
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Authorizing the Chairman of the Company to Use Its Own Funds to Entrust Financial Management
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Content Reminder:
● Entrusted Wealth Management Amount: Authorizes the Chairman of the Board to exercise the decision-making power of entrusted wealth management not exceeding RMB billion, within which funds can be used on a rolling basis, however, the total entrusted financial balance of surviving at any point in time shall not exceed 5 .4 billion yuan.
● Entrusted Wealth Management Investment Type: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
● Entrusted financial management period: the period of each investment business shall not exceed 12 months.
1. overview
(I) basic situation
1 , principle: take "standard operation, risk prevention, prudent investment, value preservation and appreciation" as the principle.
2 , Varieties: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
3 . Funds: own funds.
4 , authorized amount and term: the chairman of the board of directors is authorized to exercise the decision-making power of entrusted financial management not exceeding RMB 5 .3 billion yuan. within the amount, the funds can be used on a rolling basis, but the total balance of entrusted financial management existing at any time point shall not exceed RMB 5 .5 billion yuan. The term of each entrusted financial management shall not exceed 12 months. The authorization period shall be valid for 3 years from the date of approval by the Board of Directors of the Company. The specific investment activities are organized and implemented by the Company's Finance Department.
5 , Implementation Method: Authorize the chairman of the board to decide on matters related to entrusted financial investment within the above amount, including but not limited to: selecting qualified professional financial institutions, selecting specific types of entrusted financial products, specifying the amount and term of entrusted financial management, signing relevant contracts and agreements, etc.
(II) the approval procedures to be performed within the company
2019 , Zhejiang Jianfeng Group Co., Ltd. held the 106 meeting of the 10th board of directors, of which eight directors attended the meeting in person, director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on on his behalf. complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, with 9 votes in favor, 0 votes against, and 0 abstentions, the "Proposal on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management " was deliberated and passed.
2. Main Contents
(I) Entrusted Funds Source: Own Funds .
Impact of (II) on the Company
1 . The entrusted financial management of the Company is implemented on the premise of ensuring the daily operation and capital safety of the Company, and does not affect the daily capital turnover of the Company or the normal development of the Company's business.
2 . Through moderate and low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.
(III) Risk Control Analysis
Company strictly follows the approval and implementation procedures of "Entrusted Financial Management System" to ensure the effective development and standardized operation of entrusted financial management and other investment businesses. However, as the financial market is greatly affected by the economic environment, it is not ruled out that investment businesses such as investment and wealth management will be affected by market fluctuations. The company will take the following measures:
( 1 ) The company will clearly assign special personnel to be responsible for the relevant work of such investment matters: the chairman of the company exercises the investment decision-making power and signs relevant contract documents, the company's financial director is responsible for organizing the implementation, and the finance department is responsible for the specific operation.
( 2 ) The company's finance department is responsible for timely analyzing and tracking the investment direction of financial products and the progress of investment projects. If the evaluation finds that there are conditions that may affect the company's capital security or affect the normal capital flow demand, corresponding preservation or redemption measures will be taken in time to control investment risks.
( 3 ) The audit department of the company is responsible for auditing and supervising various investments, and regularly auditing and verifying the progress, profit and loss, and risk control of entrusted financial management. According to the principle of prudence, evaluate the possible risks and benefits of various entrusted financial management and report to the audit committee of the board of directors.
( 4 ) The company fulfills its information disclosure obligations in strict accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
(IV) Independent Director Opinion
The independent director of the company issued an independent opinion on the resolution, and believed that: the company's entrusted financial management is implemented on the premise of ensuring the company's daily operation and capital safety. It does not affect the company's daily capital turnover and does not affect the normal development of the company's business operations. By carrying out moderate low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.# The 174 has not found any damage to the rights and interests of the company and small and medium-sized shareholders. Agree to authorize the chairman to use his own funds for entrusted financial management.
"Announcement on the Progress of Entrusted Financial Management" on 2019 . As of the date of this announcement, the company has recovered all the entrusted financial management due.
As of the date of this announcement, the company's accumulated amount of entrusted financial management is 2.5 .4 billion yuan. See the following table for details:
| Trustee
| Financial Product Type
| Amount
(RMB 10,000)
| Start Date
| Due Date
|
Deadline Announcement Date recovered principal amount (RMB 10,000)
|
income as of the announcement date (RMB 10,000)
|
| 1
| Bank of Communications Jinhua Branch
|
Yuntong Wealth Fixed Term Structured Deposit
|
3,000.00
|
2019/2/1
|
2019/6/6
|
/
|
/
|
| 2
| Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB structured deposit product
|
5,000.00
|
2019/2/20
|
2019/5/21
|
/
|
/
|
|
Agricultural Bank of China Jinhua Jiangbei Sub-branch
|
Huili Feng 2019 4505 Issue Customized RMB Structured Deposit Product
|
5,000.00
|
2019/2/22
|
2019/5/24
|
/
|
/
|
4
|
Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB Structured Deposit Product
|
4,000.00
|
2019/4/9
|
2019/7/8
|
/
|
/
|
5
|
Bohai Bank Jinhua Branch
|
Bank Bohai S190534 Structured Deposit Financial Product
|
4,000.00
|
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31